1. Anti-infection
  2. HCV

Paritaprevir (Synonyms: ABT-450; Veruprevir)

Cat. No.: HY-12594 Purity: >98.0%
Data Sheet SDS Handling Instructions

Paritaprevir is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50 values of 1 and 0.21 nM for HCV 1a and 1b, respectively.

For research use only. We do not sell to patients.
Paritaprevir Chemical Structure

Paritaprevir Chemical Structure

CAS No. : 1216941-48-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $160 In-stock
5 mg $150 In-stock
10 mg $190 In-stock
50 mg $550 In-stock
100 mg $940 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Paritaprevir is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50 values of 1 and 0.21 nM for HCV 1a and 1b, respectively.

IC50 & Target

EC50: 1 nM(HCV 1a), 0.21 nM(HCV 1b)[1]

In Vitro

Paritaprevir demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a[2].

In Vivo

The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1[1].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01704755 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis October 2012 Phase 3
NCT01911845 AbbVie Chronic Hepatitis C Infection|Chronic Hepatitis C April 2013 Phase 2
NCT01091649 Abbott Healthy February 2010 Phase 1
NCT01674725 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection August 2012 Phase 3
NCT02534870 AbbVie Healthy Volunteer September 2015 Phase 1
NCT02068222 AbbVie Chronic Hepatitis C|Hepatitis C Virus April 2014 Phase 2
NCT01672983 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection July 2012 Phase 2
NCT02023112 AbbVie Hepatitis C Virus January 2014 Phase 3
NCT02052362 AbbVie Absolute Bioavailability January 2014 Phase 1
NCT02476617 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 3
NCT02493855 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 2
NCT02517528 AbbVie Chronic Hepatitis C Virus July 2015 Phase 3
NCT01685203 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C, Chronic August 2012 Phase 2
NCT02167945 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 June 12, 2014 Phase 3
NCT02219490 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 October 30, 2014 Phase 3
NCT01221298 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 October 2010 Phase 2
NCT01306617 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus February 2011 Phase 2
NCT01767116 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection December 2012 Phase 3
NCT02356562 AbbVie Chronic Hepatitis C Infection February 3, 2015 Phase 2
NCT01458535 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C Virus September 2011 Phase 2
NCT02023099 AbbVie Chronic Hepatitis C Infection December 2013 Phase 3
NCT01833533 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT01716585 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT01715415 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT02517515 AbbVie Chronic Hepatitis C Virus July 16, 2015 Phase 3
NCT02292719 AbbVie Chronic Hepatitis C Virus Infection December 19, 2014 Phase 2
NCT01074008 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 March 2010 Phase 2
NCT02265237 AbbVie Hepatitis C Virus October 28, 2014 Phase 3
NCT00931281 Abbott HCV Infection June 2009 Phase 1
NCT00909311 Abbott HCV Infection May 2009 Phase 1
NCT00850044 Abbott HCV Infection February 2009 Phase 1
NCT01939197 AbbVie Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics August 2013 Phase 3
NCT01854528 AbbVie Chronic Hepatitis C Infection June 2013 Phase 3
NCT01464827 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 October 2011 Phase 2
NCT01854697 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT01563536 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection February 2012 Phase 2
NCT01782495 AbbVie Chronic Hepatitis C Infection February 25, 2013 Phase 2
NCT01609933 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 December 18, 2012 Phase 2
NCT01773070 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C June 2013 Phase 3
NCT01995071 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis November 2013 Phase 2
NCT01704755 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis October 2012 Phase 3
NCT01911845 AbbVie Chronic Hepatitis C Infection|Chronic Hepatitis C April 2013 Phase 2
NCT01091649 Abbott Healthy February 2010 Phase 1
NCT01674725 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection August 2012 Phase 3
NCT02534870 AbbVie Healthy Volunteer September 2015 Phase 1
NCT02068222 AbbVie Chronic Hepatitis C|Hepatitis C Virus April 2014 Phase 2
NCT01672983 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection July 2012 Phase 2
NCT02023112 AbbVie Hepatitis C Virus January 2014 Phase 3
NCT02052362 AbbVie Absolute Bioavailability January 2014 Phase 1
NCT02476617 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 3
NCT02493855 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 2
NCT02517528 AbbVie Chronic Hepatitis C Virus July 2015 Phase 3
NCT01685203 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C, Chronic August 2012 Phase 2
NCT02167945 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 June 12, 2014 Phase 3
NCT02219490 AbbVie Chronic Hepatitis C Virus (HCV) Infection Genotype 1 October 30, 2014 Phase 3
NCT01221298 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 October 2010 Phase 2
NCT01306617 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus February 2011 Phase 2
NCT01767116 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection December 2012 Phase 3
NCT02356562 AbbVie Chronic Hepatitis C Infection February 3, 2015 Phase 2
NCT01458535 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C Virus September 2011 Phase 2
NCT02023099 AbbVie Chronic Hepatitis C Infection December 2013 Phase 3
NCT01833533 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT01716585 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT01715415 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection November 2012 Phase 3
NCT02517515 AbbVie Chronic Hepatitis C Virus July 16, 2015 Phase 3
NCT02292719 AbbVie Chronic Hepatitis C Virus Infection December 19, 2014 Phase 2
NCT01074008 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 March 2010 Phase 2
NCT02265237 AbbVie Hepatitis C Virus October 28, 2014 Phase 3
NCT00931281 Abbott HCV Infection June 2009 Phase 1
NCT00909311 Abbott HCV Infection May 2009 Phase 1
NCT00850044 Abbott HCV Infection February 2009 Phase 1
NCT01939197 AbbVie Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics August 2013 Phase 3
NCT01854528 AbbVie Chronic Hepatitis C Infection June 2013 Phase 3
NCT01464827 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 October 2011 Phase 2
NCT01854697 AbbVie Chronic Hepatitis C Infection March 2013 Phase 3
NCT01563536 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection February 2012 Phase 2
NCT01782495 AbbVie Chronic Hepatitis C Infection February 25, 2013 Phase 2
NCT01609933 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 December 18, 2012 Phase 2
NCT01773070 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C June 2013 Phase 3
NCT01995071 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis November 2013 Phase 2
NCT02609659 AbbVie Chronic Hepatitis C Infection October 2015 Phase 3
NCT02582632 AbbVie Hepatitis C Infection|Hepatitis C Virus November 2015 Phase 3
NCT02219503 AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis September 2014 Phase 3
NCT03122132 Hepa C Hepatitis C Infection February 20, 2017
NCT02399345 AbbVie Chronic Hepatitis C Virus (HCV Infection Genotype 1) March 2015 Phase 3
NCT02806362 AbbVie Chronic Hepatitis C Virus September 2016 Phase 3
NCT02504099 AbbVie Chronic Hepatitis C Infection July 2015 Phase 3
NCT02219477 AbbVie Chronic Hepatitis C|Decompensated Cirrhosis|Hepatitis C Virus November 24, 2014 Phase 3
NCT02216422 AbbVie Chronic Hepatitis C Virus (HCV) Infection September 2014 Phase 3
NCT02487199 AbbVie HCV|Genotype 1a|Genotype 4|Chronic Kidney Disease|Hepatitis C|pegIFN|IFN September 2015 Phase 3
NCT03067883 Ain Shams University Chronic Hepatitis c November 9, 2016 Phase 2
NCT02442284 AbbVie Chronic Hepatitis C|Cirrhosis|Hepatitis C Virus May 2015 Phase 3
NCT02207088 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease September 2014 Phase 3
NCT02442271 AbbVie Chronic Hepatitis C Infection April 2015 Phase 3
NCT02950870 University of Modena and Reggio Emilia Chronic Hepatitis, C Virus December 2016 Phase 4
NCT02461745 Kaiser Permanente|AbbVie Hepatitis C, Chronic June 2015 Phase 4
NCT02634008 Kirby Institute|AbbVie Hepatitis C, Acute June 2016 Phase 3
NCT02486406 AbbVie Chronic Hepatitis C Infection October 28, 2015 Phase 3
NCT02786537 University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme Corp.|AbbVie Chronic Hepatitis C June 2016 Phase 4
NCT02707952 AbbVie Chronic Hepatitis C Virus|Hepatitis C Virus February 2016 Phase 3
NCT02194998 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections August 2015 Phase 2
NCT02555943 Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University Chronic Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation February 2015 Phase 2|Phase 3
NCT02758509 Parc de Salut Mar Chronic Hepatitis C|Cirrhosis January 1, 2010
NCT02460133 Lisa Barrett|PEI Provincial Correction Centre|Nova Scotia Health Authority Hepatitis C Virus July 2015 Phase 4
NCT02333292 Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias|Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell Chronic Hepatitis C Infection December 2014
View MoreCollapse
References
Molecular Weight

765.88

Formula

C₄₀H₄₃N₇O₇S

CAS No.

1216941-48-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: >98.0%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Paritaprevir
Cat. No.:
HY-12594
Quantity: